Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma


Journal Article

Full Text

Duke Authors

Cited Authors

  • Nieto, Y; Thall, PF; Ma, J; Valdez, BC; Ahmed, S; Anderlini, P; Popat, U; Jones, RB; Shpall, EJ; Hosing, C; Qazilbash, M; Kebriaei, P; Alousi, A; Timmons, M; Gulbis, A; Myers, A; Oki, Y; Fanale, M; Dabaja, B; Pinnix, C; Milgrom, S; Champlin, R; Andersson, BS

Published Date

  • August 2018

Published In

Volume / Issue

  • 24 / 8

Start / End Page

  • 1602 - 1609

Published By

International Standard Serial Number (ISSN)

  • 1083-8791

Digital Object Identifier (DOI)

  • 10.1016/j.bbmt.2018.02.020


  • en